New Diabetic Treatment by Alleviation of Autonomic Nervous System Dysfunction Measured as Periosteal Pressure Sensitivity at Sternum Improves Empowerment, Treatment Satisfaction, and Self-Reported Health of People with Type 2 Diabetes: A Randomized Trial
Sofie Hecquet,Søren Ballegaard,Ebbe Eldrup,Christian Hansen,Tine Hansen,Gitte Harboe,Peter Rossing,Caroline Pichat,Torquil Watt,Finn Gyntelberg,Nanna Ørsted,Jens Faber
DOI: https://doi.org/10.2147/dmso.s455216
2024-06-20
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Sofie Korsgaard Hecquet, 1, 2, &ast Søren Ballegaard, 1, &ast Ebbe Eldrup, 1, 3 Christian Stevns Hansen, 1, 2 Tine Willum Hansen, 2, 3 Gitte Sommer Harboe, 1 Peter Rossing, 2, 3 Caroline Sophie Hjelm Pichat, 1 Torquil Watt, 1 Finn Gyntelberg, 4 Nanna Ørsted, 1 Jens Oscar Faber 1, 3 1 Department of Medicine, Endocrine Unit, Herlev Gentofte University Hospital, Herlev, Denmark; 2 Clinical and Translational Research, Complications Research, Steno Diabetes Center Copenhagen, Herlev, Denmark; 3 Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; 4 The National Research Center for the Working Environment, Copenhagen, Denmark &astThese authors contributed equally to this work Correspondence: Sofie Korsgaard Hecquet, Clinical and Translational Research, Complications Research, Steno Diabetes Center Copenhagen, Borgmester Ib Juuls vej 83, Herlev, Copenhagen, 2730, Denmark, Tel +45 30913413, Email Purpose: Autonomic nervous system dysfunction (ANSD), for which presently no treatment exists, has a negative impact on prognosis in people with type 2 diabetes (T2D). Periosteal pressure sensitivity (PPS) on sternum may be a measure of autonomic nervous system dysfunction (ANSD). We tested if a non-pharmacological PPS-feedback-guided treatment program based on non-noxious sensory nerve stimulation, known to reduce PPS, changed empowerment, treatment satisfaction, and quality of life in people with T2D, compared to usual treatment. Patients and Methods: Analysis of secondary endpoints in a single center, two-armed, parallel-group, observer-blinded, randomized controlled trial of individuals with T2D. Participants were randomized to non-pharmacological intervention as an add-on to treatment as usual. Endpoints were evaluated by five validated questionnaires: Diabetes specific Empowerment (DES-SF), Diabetes Treatment Satisfaction (DTSQ), quality of life (QOL) (WHO-5), clinical stress signs (CSS), and self-reported health (SF-36). Sample size calculation was based on the primary endpoint HbA1c. Results: We included 144 participants, 71 allocated to active intervention and 73 to the control group. Active intervention compared to control revealed improved diabetes-specific empowerment (p = 0.004), DTSQ (p = 0.001), and SF-36 self-reported health (p=0.003) and tended to improve quality of life (WHO-5) (p = 0.056). The findings were clinically relevant with a Cohen's effect size of 0.5 to 0.7. Conclusion: This non-pharmacological intervention, aiming to reduce PPS, and thus ANSD, improved diabetes-specific empowerment, treatment satisfaction, and self-reported health when compared to usual treatment. The proposed intervention may be a supplement to conventional treatment for T2D. Keywords: type 2 diabetes, empowerment, autonomic nervous system dysfunction, periosteal pressure sensitivity An estimated number of 537 million individuals worldwide are diagnosed with diabetes, of which 90–95% are type 2 diabetes (T2D). This may rise to 784 million in 2050 according to the International Diabetes Federation, with substantial and increasing social expenses. 1 In addition to medication, contemporary treatments include adjustments to the lifestyle, including diet and physical exercise. Low adherence to the lifestyle-related intervention program is a general challenge. 2,3 A cornerstone in the treatment of T2D is the principle of personal empowerment by structured education aimed at increased individual responsibility for disease management. The management includes exercise programs, diet plans, and repeated blood glucose measurements at home, used to guide behavior. 4 Defining empowerment, WHO has stated that it is "a process through which people gain control over decisions and actions affecting health", and it should be solved individually as well as in the community. 5 The autonomic nervous system (ANS) controls the functions of the body by maintaining a balance between two opposing and interconnected systems - the sympathetic and parasympathetic nervous systems. Autonomic nervous system dysfunction (ANSD), characterized by sympathetic predominance, is linked to the onset of type 2 diabetes (T2D), disrupted glucose metabolism, and poor outcomes of T2D, leading to increased co-morbidities such as cardiovascular disease, renal insufficiency, and peripheral neuropathy and increased mortality. 6–8 Intuitively, alleviation of ANSD would be of potential clinical importance. However, no existing treatment modality exist -Abstract Truncated-
endocrinology & metabolism